New Medication Data Collection for 2026: GLP-1 and SGLT-2

A man prepares to inject a dose of Ozempic.

Starting with January 2026 discharges, BMC2 is collecting data on two important classes of medications: GLP-1 agonists (for example, Ozempic and Trulicity) and SGLT-2 inhibitors (for example, Jardiance and Invokana).

These medications are often used for diabetes, but we will collect this data for all patients regardless of diagnosis.

Including these medications helps us understand more about medication usage and emerging therapies in vascular surgery patients.

Thank you for your continued commitment to improving quality of care and outcomes for cardiovascular patients across Michigan.